

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 4133

DUGAN ET AL.

Examiner: Teale, Michael J

APPLICATION NO: 10/528,914

FILED: JANUARY 5, 2006

FOR: USE OF 4-PYRIDYLMETHYL-PHTHALAZINE DERIVATIVES FOR
THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT
OF MYELODYSPLASTIC SYNDROMES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-7824

Date: 5/28/09

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
DUGAN ET AL.

Art Unit: 4133

Examiner: Teale, Michael J

INTERNATIONAL APPLICATION NO: PCT/EP03/10578

FILED: 23 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,914

35 USC §371 DATE: 5 JANUARY 2006

FOR: USE OF 4-PYRIDYLMETHYL-PHTHALAZINE DERIVATIVES FOR
THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT
OF MYELODYSPLASTIC SYNDROMES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed March 23, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

Copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, reading "George R. Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-7824

Date: 5/28/09